CD274 and neoplasm: Several clinical and biomarker tools have been explored to predict the rate of pCR achievement [45]: stromal tumor-infiltrating lymphocytes (sTILs), programmed-death ligand-1 status (PD-L1), and certain gene signatures, among others, have shown promising but inconclusive results.